Innogen Commences Phase II Trial of Efsubaglutide Alfa for Obesity in Australia
CompanyDrug

Innogen Commences Phase II Trial of Efsubaglutide Alfa for Obesity in Australia

Humanwell Secures NMPA Approval for Remimazolam ICU Sedation
CompanyDrug

Humanwell Secures NMPA Approval for Remimazolam ICU Sedation

Eisai & Biogen Launch Lecanemab in Austria & Germany – First Cause‑Based Alzheimer’s Therapy
CompanyDrug

Eisai & Biogen Launch Lecanemab in Austria & Germany – First Cause‑Based Alzheimer’s Therapy

BioArctic & Novartis Announce BrainTransporter‑Enabled Neurodegeneration Collaboration – Up to $772 M Potential Pay‑Out
Others

BioArctic & Novartis Announce BrainTransporter‑Enabled Neurodegeneration Collaboration – Up to $772 M Potential Pay‑Out

Anke Biotech Secures Long‑Acting FSH‑CTP Approval in China
CompanyDrug

Anke Biotech Secures Long‑Acting FSH‑CTP Approval in China

Cloudbreak Pharma Profit Highlights Turnaround in Ophthalmic Biotech
Company

Cloudbreak Pharma Profit Highlights Turnaround in Ophthalmic Biotech

Minova Rongzhi Funding Surge: Series B Backed by IDG Capital
CompanyDeals

Minova Rongzhi Funding Surge: Series B Backed by IDG Capital

Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment
Company

Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment

AbbVie Acquires Bretisilocin from Gilgamesh in $1.2B Deal for MDD Treatment
CompanyDeals

AbbVie Acquires Bretisilocin from Gilgamesh in $1.2B Deal for MDD Treatment

Hengrui Pharmaceuticals Secures NMPA Approval for HRS‑2162 and HRS‑6093 Clinical Trials
CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Approval for HRS‑2162 and HRS‑6093 Clinical Trials

Yichang Humanwell Partners with DP Technology to Leverage Hermite Platform for Drug Discovery
CompanyDeals

Yichang Humanwell Partners with DP Technology to Leverage Hermite Platform for Drug Discovery

Wusheng Erlunbao: Sinopharm’s First‑of‑Its‑Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval
CompanyDrug

Wusheng Erlunbao: Sinopharm’s First‑of‑Its‑Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval